Senti Biosciences (NASDAQ:SNTI) Trading Down 3.2% – Here’s What Happened

Senti Biosciences, Inc. (NASDAQ:SNTI)’s share price traded down 3.2% on Thursday . The stock traded as low as $0.4203 and last traded at $0.4266. 117,052 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 356,246 shares. The stock had previously closed at $0.4405.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SNTI. Wall Street Zen raised shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research note on Friday, July 17th. Finally, Chardan Capital increased their price objective on Senti Biosciences from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Senti Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Senti Biosciences Stock Performance

The company has a 50 day moving average of $0.92 and a 200 day moving average of $0.95. The firm has a market cap of $13.29 million, a P/E ratio of -0.22 and a beta of 2.04.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.22. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. As a group, analysts expect that Senti Biosciences, Inc. will post -1.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Armistice Capital LLC acquired a new position in Senti Biosciences during the second quarter worth $1,883,000. Geode Capital Management LLC lifted its position in shares of Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Senti Biosciences during the 3rd quarter worth about $117,000. Virtu Financial LLC bought a new stake in shares of Senti Biosciences during the 4th quarter worth about $46,000. Finally, Jane Street Group LLC bought a new stake in shares of Senti Biosciences during the 4th quarter worth about $40,000. Institutional investors own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.